Show simple item record

dc.contributor.authorTazi, Y.
dc.contributor.authorOssa, J. A.
dc.contributor.authorZhou, Y. Y.
dc.contributor.authorBernard, E.
dc.contributor.authorThomas, I.
dc.contributor.authorGilkes, A.
dc.contributor.authorFreeman, S.
dc.contributor.authorPradat, Y.
dc.contributor.authorJohnson, S.
dc.contributor.authorHills, R.
dc.contributor.authorDillon, R.
dc.contributor.authorLevine, M.
dc.contributor.authorLeongamornlert, D.
dc.contributor.authorButler, A.
dc.contributor.authorGanser, A.
dc.contributor.authorBullinger, L.
dc.contributor.authorDohner, K.
dc.contributor.authorOttmann, O.
dc.contributor.authorAdams, R.
dc.contributor.authorDohner, H.
dc.contributor.authorCampbell, P.
dc.contributor.authorBurnett, A.
dc.contributor.authorDennis, Michael
dc.contributor.authorRussell, N.
dc.contributor.authorDevlin, S.
dc.contributor.authorHuntly, B.
dc.contributor.authorPapaemmanuil, E.
dc.date.accessioned2022-08-31T11:38:44Z
dc.date.available2022-08-31T11:38:44Z
dc.date.issued2022en
dc.identifier.citationTazi Y, Ossa JA, Zhou YY, Bernard E, Thomas I, Gilkes A, et al. Unified classification and risk-stratification in Acute Myeloid Leukemia. Nature communications. 2022 Aug;13(1). PubMed PMID: WOS:000837856500001.en
dc.identifier.pmid35941135en
dc.identifier.doi10.1038/s41467-022-32103-8en
dc.identifier.urihttp://hdl.handle.net/10541/625598
dc.description.abstractClinical recommendations for Acute Myeloid Leukemia (AML) classification and risk-stratification remain heavily reliant on cytogenetic findings at diagnosis, which are present in <50% of patients. Using comprehensive molecular profiling data from 3,653 patients we characterize and validate 16 molecular classes describing 100% of AML patients. Each class represents diverse biological AML subgroups, and is associated with distinct clinical presentation, likelihood of response to induction chemotherapy, risk of relapse and death over time. Secondary AML-2, emerges as the second largest class (24%), associates with high-risk disease, poor prognosis irrespective of flow Minimal Residual Disease (MRD) negativity, and derives significant benefit from transplantation. Guided by class membership we derive a 3-tier risk-stratification score that re-stratifies 26% of patients as compared to standard of care. This results in a unified framework for disease classification and risk-stratification in AML that relies on information from cytogenetics and 32 genes. Last, we develop an open-access patient-tailored clinical decision support tool.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41467-022-32103-8en
dc.titleUnified classification and risk-stratification in Acute Myeloid Leukemiaen
dc.typeArticleen
dc.contributor.departmentComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NYen
dc.identifier.journalNature Communicationsen
dc.description.noteen]
refterms.dateFOA2022-08-31T12:36:24Z


Files in this item

Thumbnail
Name:
35941135.pdf
Size:
3.934Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record